Clinicopathology Figures and Survival of Non-Hodgkin’s Lymphoma in Iran

Background Non-Hodgkin’s lymphoma (NHL) is the fifth most frequently diagnosed cancer whose incidence has risen by at least 100 percent over the past five decades especially in the West. Objectives The aim of this study is to investigate Clinicopathology figures, overall survival (OS) and Progression-free survival (PFS) in patients with NHL in Iran. Methods In a descriptive study, 143 patients referred to Clinic of Hematology in two centers between 2005 and 2014. We checked age, sex, types and subtypes of NHL; recurrence, Ki-67, organomegaly, lymphadenopathy, radiotherapy, OS and PFS in the patients. The mean follow-up was 49 months. All patients received R-CHOP regimen for 6 to 8 cycles. Results The mean age at diagnosis for the patients was 46 years (range, 16 - 82) and 76.9% had age < 60 years and 62.2% were male. 58% patients had primary nodal NHL and out of 139 patients, 88.5% were aggressive NHL. Organomegaly and lymphadenopathy were in 12 patients (8.4%) and 80 (55.9%), respectively. Of all patients, 106 patients (74.1%) were treated with radiotherapy. 2-year OS rate was 91.5% and 5-year OS rate was 85%.2-and 5-year PFS rates were 79.6% and 63.3%, respectively. Conclusions Percentage of NHL in males is more than females and the median age is around 45 years. Also, the prevalence of nodal is more compared with extranodal in NHL patients.